Simple Summary The breakthrough of immunotherapy in melanoma has generated a
glimmer of hope for lethal triple negative breast cancer (TNBC). This review summarizes the …

Breast cancer is the most common malignant tumor in females worldwide. Chemotherapy is
the standard breast cancer treatment; however, chemoresistance is often seen in patients …

Immune-checkpoint inhibitors (ICI) are promising modalities for treating triple negative
breast cancer (TNBC). However, hyperglycolysis, a hallmark of TNBC cells, may drive tumor …

Background Abundant evidence shows that triple-negative breast cancer (TNBC) is
heterogeneous, and many efforts have been devoted to identifying TNBC subtypes on the …

Despite the success of immune checkpoint blockade (ICB) therapy in cancer management,
ICB-based immunotherapy of triple-negative breast cancer (TNBC) still suffers from …

New strategies to block the immune evasion activity of programmed death ligand-1 (PD-L1)
are urgently needed. When exploring the PD-L1-targeted effects of mechanistically diverse …

Lack of tumor‐infiltration lymphocytes (TILs) and resistances by overexpressed
immunosuppressive cells (principally, myeloid‐derived suppressor cells (MDSCs)) in tumor …

Cancer immunotherapy has been heralded as a breakthrough cancer treatment
demonstrating tremendous success in improving tumor responses and survival of patients …

Triple-negative breast cancer (TNBC) has the worst prognosis among the subtypes of breast
cancer, with no targeted therapy available. Immunotherapy targeting programmed cell death …

Long non-coding RNA (lncRNA) DANCR (also known as ANCR)—differentiation
antagonizing non-protein coding RNA, was first reported in 2012 to suppress differentiation …